Amer Amin

Amer Amin

Auto-generated profile, based on publicly available information

Amer Amin

St. Vincent’s Prostate Cancer Research Centre, Darlinghurst, Australia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

14 November 2019 in BJU International
Verified
Journal Article
Closed access
PDF file
ABAlexandar Blazevski
Alexandar Blazevski
MSMatthijs J. Scheltema
Matthijs J. Scheltema
AAAmer Amin
Amer Amin
JTJames E. Thompson
James E. Thompson
NLNathan Lawrentschuk
Nathan Lawrentschuk
PSPhillip D. Stricker
Phillip D. Stricker

2 June 2020 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
ABAlexandar Blazevski
Alexandar Blazevski
AAAmer Amin
Amer Amin
MSMatthijs J. Scheltema
Matthijs J. Scheltema
ABAnjali Balakrishnan
Anjali Balakrishnan
AHAnne-Maree Haynes
Anne-Maree Haynes
PSPhillip D. Stricker
Phillip D. Stricker

2 March 2022 in BMC Urology
Verified
Journal Article
Open access
PDF file
ABAlexandar Blazevski
Alexandar Blazevski
WGWilliam Gondoputro
William Gondoputro
MSMatthijs J. Scheltema
Matthijs J. Scheltema
AAAmer Amin
Amer Amin
BGBart Geboers
Bart Geboers
PSPhillip D. Stricker
Phillip D. Stricker
Background: To report the feasibility, oncological and functional outcomes of salvage robot-assisted radical prostatectomy (sRARP) for recurrent prostate cancer (PCa) after irreversible electroporation (IRE). Methods: This was a retrospective analysis of patients who underwent sRARP by a single high-volume surgeon after IRE treatment in our institution. Surgical complications, oncological and functional outcomes were assessed. Results: 15 patients with at least 12 months follow up were identified out of the 234 men who underwent primary IRE between 2013 and 2019. The median [IQR] age was 68 (62–70) years. The median [IQR] time from focal IRE to sRARP was 42 (21–57) months. There were no rectal, bladder or ureteric injuries. The T-stage was pT2 in 9 (60%) patients and pT3a in 6 (40%) patients. Only one (7%) patient had a positive surgical margin. At a median [IQR] follow up of 22 (16–32) months no patient had a biochemical recurrence (PSA > 0.2). All 15 patients were continent (pad-free) by 6 months and 9 (60%) patients had erections sufficient for intercourse with or without PDE5 inhibitors. No predisposing factors were identified for predicting erectile dysfunction after sRARP. Conclusions: In patients with recurrent or residual significant PCa after focal IRE ablation it is feasible to obtain good functional and oncological outcomes with sRARP. Our results demonstrate that good outcomes can be achieved with sRARP, when respecting close monitoring post-IRE, good patient selection and surgical experience. The limitations of this study are that it is a small series, with short follow up and a lack of standardised quality of life instruments.